TSW
HUMA icon

Thompson Siegel & Walmsley’s Humacyte HUMA Stock Holding History

Thompson Siegel & Walmsley’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-92,000
Closed -$192K – 421
2025
Q2 		$192K Hold
92,000
– – ﹤0.01% 393
2025
Q1 		$157K Buy
92,000
+57,000
+163% +$214K ﹤0.01% 382
2024
Q4 		$177K Buy
+35,000
New +$173K ﹤0.01% 375

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Thompson Siegel & Walmsley's HUMA Position: Q3 2025 in Review

Thompson Siegel & Walmsley sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 92,000 shares — an estimated $192K sold.

Thompson Siegel & Walmsley first reported a position in HUMA in Q4 2024 and held it in 3 quarters. The position peaked at $192K in Q2 2025. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

  • Thompson Siegel & Walmsley reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 92,000 Humacyte shares in Q3 2025, an estimated $192K.
  • Thompson Siegel & Walmsley first reported a position in Humacyte in Q4 2024 and held it in 3 quarters.
  • Thompson Siegel & Walmsley's Humacyte position peaked at $192K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on Thompson Siegel & Walmsley's 13F filing for Q3 2025, filed 12 Nov 2025.